Cannabis Law Report

JUNE 11, 2023

The US Drug Enforcement Administration (DEA) issued a letter on June 9, 2023 in response to a request about information regarding, among other things, tetrahydrocannabinolic acid (THCa). A copy of the letter is below. Note that I was only able to locate a copy of the letter on Reddit. I had to compile a series […]

DEA 52

DEA 52

The Blunt Truth

DECEMBER 29, 2023

We thought the market would expand “quite a bit” in 2023 – well, the “a bit” part was right. And not to ruin the ending, but no retail market will open in 2023. As of now, this is still a proposal, and it’s anyone’s guess if the DEA (who would do the actual re-scheduling) will think that’s a good idea. by a large margin.

DEA 52

DEA Retail Legalization Food 52

The Blunt Truth

DECEMBER 15, 2023

The DEA sends a letter to Georgia pharmacies. Well, apparently the Drug Enforcement Administration (DEA) noted that as well, and they didn’t take kindly to it. But wait, isn’t there a provision that prohibits the Department of Justice (of which DEA is a part) from interfering with state legal medical marijuana programs?

DEA 59

DEA Legislation Legalization Consumption 59

Cannabis Law Report

FEBRUARY 13, 2023

February 13, 2023 Business and Commerce Law, Distributors, I have been concerned about the proliferation of THC acetate ester (THCO) for a while. It has always been my view that THCO is a controlled substance under federal law. Although it can be made from cannabinoids from hemp, THCO is not naturally expressed by the hemp plant.

DEA 52

DEA Hemp Cannabinoids THC 52

Cannabis Law Report

MARCH 9, 2023

LaBruyere on March 9, 2023 Last week, we wrote about the Drug Enforcement Administration’s (DEA) February 13, 2023 response letter stating that delta-8 THCO and delta-9 THCO – two forms of THC acetate ester (THCO) – are illegal controlled substances under federal law. The DEA’s decision centered on THCO’s “synthetic” nature.

DEA 52

DEA THC Legalization Law 52

Cannabis Law Report

AUGUST 12, 2022

Marijuana Moment report on some of the panels being proposed for 2023…… Voting is now open for the public to decide which panels will make the stage at next year’s South By Southwest (SXSW) festival—and there are about 100 marijuana- and psychedelics-related proposals to pick from. Which Political Party Will Legalize Weed?

Research and Development 52

Research and Development Topical Events Policy 52

The Blunt Truth

DECEMBER 22, 2023

UNITED STATES ATTORNEYS Attorney General Merrick Garland and DEA Administrator Anne Milgram received a letter this week from several former United States Attorneys. GEORGIA As we reported last week, Georgia independent pharmacies received a letter from the DEA telling them to stop selling medical cannabis products.

DEA 52

DEA Retail Programs Hemp 52

Cannabis Law Report

FEBRUARY 22, 2023

February 21 2023 On February 13, I posted an article about the DEA’s response to my inquiry regarding the legal status of THCO. As my readers are aware, the DEA stated that THCO is a schedule 1 controlled substance. The DEA’s position, which was spread via my article, created what several people have called a “shitstorm”.

DEA 59

DEA Legalization 59

Cannabis Law Report

OCTOBER 6, 2021

Bright Green will be operating under a Memorandum of Agreement with the Drug Enforcement Administration (DEA). Construction on the facility is scheduled to be completed in 2023. According to a press release by the company, they intend for the facility to be part of a larger national market for cannabis research and products.

DEA 52

DEA Therapy Environment Agriculture 52

Cannabis Law Report

OCTOBER 4, 2021

Adult Oregonians will be able to access psilocybin therapy under the PSA beginning in January 2023; patients with advanced illness are among those who may benefit from this therapy. Litigation to compel DEA to respect RTT laws and allow access to psilocybin for therapeutic use is pending before the Ninth Circuit Court of Appeals.

Therapy 52

Therapy Patients Law Clinical Trials 52

Veriheal

MARCH 6, 2024

Department of Health and Human Services (HHS) recommended that the Drug Enforcement Agency (DEA) reshedule cannabis as a Schedule III substance in August of 2023. The recommendation for rescheduling cannabis marked the first time a government agency officially recognized cannabis’ medical benefits.

Research and Development 64

Research and Development DEA Chronic Pain Business 64

Veriheal

DECEMBER 27, 2022

In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. . It’s excellent news, particularly since new research suggests psilocybin deserves further investigation.

Research and Development 102

Research and Development Therapy Consumption DEA 102

Cannabis Law Report

JULY 28, 2022

Testimonies by Wang and Quarles urged committee members to incorporate language into the 2023 Farm Bill that would regulate CBD and other hemp-derived compounds. Wang encouraged committee members to incorporate language into the 2023 Farm Bill found in H.R. The panel’s leaders agreed; Ranking Member Rep. Watch the exchange here.

Agriculture 52

Agriculture Hemp CBD Research and Development 52

SpeedWeed

MAY 15, 2021

Doblin and his fellow researchers initially began exploring the therapeutic potential of MDMA back in the early 1980s, but these studies ground to a halt when the DEA banned ecstasy in 1985. If all goes well, the FDA could legalize MDMA-assisted therapy next year, which would make it legally available starting in 2023.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

MAY 31, 2022

Stay tuned… Oregon plans to accept applications for Facilitators, Laboratories, Manufacturers and Service Centers starting January 2023. The Drug Enforcement Agency (DEA) currently has guidance published for those interested in petitioning for a religious exemption to the CSA. Non-Commercial Operations. Underground Therapists.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

AUGUST 18, 2022

Study and development of these treatments remain challenging as psilocybin, MDMA, DMT and LSD are all listed as DEA Schedule I drugs. It is anticipated that MDMA will receive FDA approval for PTSD by the end of 2023, and that psilocybin approval will follow. However, change appears imminent.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

APRIL 21, 2022

MDMA is a promising psychedelic compound, currently placed by the Drug Enforcement Administration (DEA) in Schedule I of the Controlled Substances Act, that has been produced for legal research in small batches by certified laboratories. Berra Yazar-Klosinski, Ph.D. contributing author and MAPS PBC Chief Scientific Officer.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

DECEMBER 21, 2021

It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. The company, which began trading on the OTC and Frankfurt Stock exchanges in October, has plans to open as many as 120 more clinics by 2023. Also in November, it reported positive data on its standout IND, CYB003.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

NOVEMBER 11, 2021

In fact, the United States Drug Enforcement Agency (DEA) issued a private letter ruling in September 2021 making clear that so long as Delta-8 has been extracted from a hemp plant (rather than a marijuana plant that contains.3% ” Under this timeline, New Yorkers can expect to see retail sales in approximately April of 2023.

Programs 52

Programs Hemp Supply Chain Seed-To-Sale 52

Cannabis Law Report

AUGUST 6, 2021

“We’re continuing to drive cost savings and operational efficiencies across the company, and remain broadly on track to our target of $150 – $200 million in fiscal 2022- fiscal 2023,” added Mike Lee , CFO. “We Drug Enforcement Administration (the “DEA”), the U.S. First Quarter Fiscal 2022 Financial Summary. hemp industry in the U.S.,

Vaping 105

Vaping Research and Development Data Business 105

Canna Law Blog

JUNE 26, 2024

The Drug Enforcement Administration (DEA) seems happy to respond to public and private parties inquiring about the control status of various substances. DEA answers some of these inquiries more quickly than others, and the response letters are usually short and to the point. What are the legal ramifications of DEA writing these things?”

DEA 109

DEA Legalization Sativa Food 109

Canna Law Blog

MAY 16, 2024

In a much anticipated announcement, the Drug Enforcement Administration (DEA) issued a notice of proposed rulemaking to reschedule marijuana, from Controlled Substances Act (CSA) schedule I to schedule III (the “Proposed Rule”). First , DEA is not proposing an interim final rule. 29, 2023) (“August 2023 Letter”).

DEA 119

DEA Marijuana History Events 119

Canna Law Blog

JUNE 26, 2024

The Drug Enforcement Administration (DEA) seems happy to respond to public and private parties inquiring about the control status of various substances. DEA answers some of these inquiries more quickly than others, and the response letters are usually short and to the point. What are the legal ramifications of DEA writing these things?”

DEA 97

DEA Legalization Sativa Food 97

Cannabis Law Report

JUNE 1, 2021

Implementation of supply chain optimization well underway with network optimization and complexity reduction initiatives expected to realize our previously stated cost savings of $150 million to $200 million by the end of the first half of FY 2023. Drug Enforcement Administration (the “DEA”), the U.S.

Data 95

Data Vaping Supply Chain Business 95

Canna Law Blog

FEBRUARY 16, 2024

Griffen’s article is just one of many parsing the language of the 2018 Farm Bill and a 2023 DEA letter on the topic. See also: “ THCA and the DEA: Rod Breaks Down the Latest News ” from Rod Kight, an another attorney prominent in the space. I would say: “Someone over at DEA wrote a letter last year indicating that it’s not.

DEA 105

DEA Seed-To-Sale Hemp Concentrates 105

Canna Law Blog

MAY 29, 2024

In my June 2023 post, I concluded that even if there are good arguments for THCA’s legality, practically speaking law enforcement was likely to consider THCA in calculating total THC, given the fact that THCA converts to THC upon application of heat. But, it bears mentioning that DEA’s interpretations are just that.

Hemp 97

Hemp DEA Seed-To-Sale THC 97

Canna Law Blog

JANUARY 8, 2025

cannabis community awaits the resumption of the DEA’s administrative law hearing on rescheduling marijuana later this month, this blog will take a glimpse at the ever-dynamic global landscape of cannabis policy. Phase I, implemented in 2023, legalized cannabis cultivation clubs, home cultivation, and personal possession.

Law 128

Law Programs Cultivation Hemp 128

Canna Law Blog

JULY 26, 2023

Revisit provisions of the Farm Bill or interpretations of the Farm Bill pushed by the DEA, which currently make hemp processors susceptible to civil penalties and felony charges for possession or transport of “hot hemp”, regardless of whether the THC limit is 0.3%, or 1.0%. But while you’re processing that hemp you may be committing felonies!,

Hemp 98

Hemp DEA THC Policy 98

The Cannigma

MAY 15, 2023

Schedule III substances are subject to certain controls not applicable to all other prescription drugs, including the requirement that a medical professional with a specific license issued by the Drug Enforcement Agency (DEA) must conduct an in-person examination before prescribing it.

Therapy 105

Therapy Access Blood Pressure Treatment 105

Canna Law Blog

NOVEMBER 21, 2021

Earlier this year, we wrote about how MAPS was progressing through the Phase III study process and was targeting FDA approval in 2022 and commercialization in 2023 — if these targets are met, they would be on par with Oregon’s legal psilocybin licensing program.

Decriminalization 98

Decriminalization DEA Conditions Legalization 98

Canna Law Blog

APRIL 24, 2023

Suffice it to say that DEA has opined that it is — at least for now. The 2018 Farm Bill is set to expire September 30, 2023. Oregon’s legislative session ends June 25, 2023. So, seeds possessed by OLCC licensees that will germinate into high THC plants would be shippable too. Will SB 353 pass?

Hemp 98

Hemp Seed-To-Sale Marijuana Cannabinoids 98

Canna Law Blog

JULY 24, 2023

REGISTER HERE If you haven’t already registered, please join us on July 25, 2023 at 10am PST for a free webinar on U.S. Drug Enforcement Administration (DEA), Customs and Border Protection (CBP) and their personnel. Import and Export of Marijuana, Hemp, and Paraphernalia. cannabis business lawyer Vince Sliwoski.

Hemp 95

Hemp Marijuana DEA Topical 95

Canna Law Blog

MARCH 21, 2022

Drug Enforcement Agency (DEA) reported that the federalization of hemp would result in hemp shielding criminal activities. Counties may also extend moratoriums, provided they submit an annual request with the ODA by January 1, 2023. In 2020, the U.S. These two counties have imposed local hemp moratoriums in accordance with SB 1564.

Hemp 98

Hemp DEA Conditions Agriculture 98

Canna Law Blog

JULY 14, 2023

On July 5, 2023, the FDA and FTC jointly announced six cease and desist letters to alleged delta-8 product makers. But, there’s a huge controversy about whether it can be controlled, with agencies like the DEA saying it is. You can access the letters here. You can read more about that issue here or here.

Packaging 98

Packaging Food Edibles THC 98

Canna Law Blog

APRIL 1, 2022

Biden would have to direct DEA, HHS and FDA to consider that, and he’s been sort of busy. And if not, the odds may dip once again headed into 2023. The Administration also may have been sidetracked updating employee conduct guidelines to potentially deny security clearance to anyone investing in a cannabis company. Probably not though.

Decriminalization 98

Decriminalization DEA Cannabis Business 98

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. 9] Experts predict that this therapy could receive full FDA approval as soon as 2023. [10] DEA and the Controlled Substances Act. Under the Controlled Substances Act of 1970, DEA classifies drugs into one of five schedules.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Connor & Connor PLLC

AUGUST 15, 2024

If Congress would like to change the legal status of marijuana, they would do so before or after the DEA makes a final scheduling decision. On May 21, 2024, the DEA opened a 62-day public comment period, which concluded on July 22, 2024. Currently, rescheduling marijuana to Schedule III of the CSA is being considered. What is 280E.

Marijuana 52

Marijuana DEA Policy Business 52